skip to Main Content

Jessica Chutter

Managing Director, Chairman of Biotechnology Investment Banking, Morgan Stanley

Jessica is the managing director and chairman of Biotechnology Investment Banking at Morgan Stanley. During Jessica’s 30-year career of building Morgan Stanley’s biotechnology franchise, she has been responsible for $30 billion of capital raising and $65B of strategic transactions. In 2017, transactions include leading financings for Axovant, Biohaven, Editas, Galapagos, RegenxBio and Syndax, aggregating $1Bn in proceeds.  Previous strategic transactions include advising Cubist on its $9.5Bn sale to Merck, Pharmasset on its $11Bn sale to Gilead and Elan on its $8.6Bn sale to Perrigo. She has also been involved in the creation of a new asset class involving royalty-backed debt (PhaRMA) where over $16 billion has been raised.

Jessica has a BA in Commerce/Honours Economics from McGill University and an MBA from Harvard Business School.

Back To Top